Drug EfficacyLifileucel exhibits impressive clinical efficacy in anti-PD-1 naïve melanoma, with a confirmed overall response rate of 65.2%, including complete and partial responses.
Insurance And AccessReimbursement is tracking well for Amtagvi, with over 75% of enrolled patients covered by private payors, and it's added as a preferred therapy in NCCN guidelines, enhancing financial accessibility and potential increased adoption.
Market AdoptionOver 100 patients have made treatment decisions to receive Amtagvi, demonstrating solid interest and uptake, with encouraging comments on the first months of the launch.